• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Evolus Inc.

    3/4/25 4:44:43 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EOLS alert in real time by email
    S-8 1 evoluss-82025.htm S-8 Document

             As filed with the Securities and Exchange Commission on March 4, 2025.

    Registration No. 333-

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    ___________________
    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
    ___________________
    Evolus, Inc.
    (Exact name of registrant as specified in its charter)
    ___________________
    Delaware46-1385614
    (State or other jurisdiction of incorporation or organization)
    (I.R.S. Employer Identification No.)

    520 Newport Center Drive, Suite 1200
    Newport Beach, California 92660
    (Address of Principal Executive Offices) (Zip Code)
    ___________________

    Evolus, Inc. 2017 Omnibus Incentive Plan
    Evolus, Inc. 2023 Inducement Incentive Plan
    (Full title of the plans)
    ___________________

    David Moatazedi
    President and Chief Executive Officer
    Evolus, Inc.
    520 Newport Center Drive, Suite 1200
    Newport Beach, California 92660
    (949) 284-4555
    (Name and address of agent for service) (Telephone number, including area code, of agent for service)
    ___________________
    Copies to:
    Jeffrey J. Plumer
    General Counsel
    Evolus, Inc.
    520 Newport Center Drive, Suite 1200
     Newport Beach, California 92660
    (949) 284-4555

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b–2 of the Exchange Act.
    Large accelerated filer☐Accelerated filer☒
    Non-accelerated filer☐Smaller reporting company☐
    Emerging growth company☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐



    EXPLANATORY NOTE

    This Registration Statement is filed by the Registrant to register additional securities issuable pursuant to each of (1) the Registrant's 2017 Omnibus Incentive Plan (the “2017 Plan”) and (2) the Registrant's 2023 Inducement Incentive Plan (the “2023 Plan”) and consists of only those items required by General Instruction E to Form S-8.
    PART I

    INFORMATION REQUIRED IN THE
    SECTION 10(a) PROSPECTUS

        The document(s) containing the information specified in Part I of Form S-8 will be sent or given to participants as specified by Securities Act Rule 428(b)(1).

    PART II

    INCORPORATION BY REFERENCE OF CONTENTS OF
    REGISTRATION STATEMENT ON FORM S-8

    Item 3.    Incorporation of Certain Documents by Reference
    The following documents of the Company filed with the Securities and Exchange Commission (the “Commission”) are incorporated herein by reference:
    (a)    The Company’s Annual Report on Form 10-K for its fiscal year ended December 31, 2024, filed with the Commission on March 4, 2025 (Commission File No. 001-38381);
    (b)    The description of the Company’s Common Stock contained in its Registration Statement on Form 8-A filed with the Commission on February 1, 2018, as modified by the description of the Company’s Common Stock contained in Exhibit 4.3 to the Company’s Annual Report on Form 10-K for its fiscal year ended December 31, 2023, filed with the Commission on March 7, 2024 (each, Commission File No. 001-38381), and any other amendment or report filed for the purpose of updating such description; and

    (c)    The Company’s Registration Statements on Form S-8 previously filed with the Commission on March 7, 2024 (File No. 333-277754), March 7, 2023 (File No. 333-270360), March 4, 2022 (File No. 333-263325), March 26, 2021 (File No. 333-254746), February 25, 2020 (File No. 333-236620), January 10, 2019 (File No. 333-229184), and February 16, 2018 (File No. 333-223068) relating to the 2017 Plan.
    (d)    The Company's Registration Statement on Form S-8 previously filed with the Commission on October 6, 2023 (File No. 333-274906) relating to the 2023 Plan.
    All documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with Commission rules shall not be deemed incorporated by reference into this Registration Statement. Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this Registration Statement.
    Item 5.    Interests of Named Experts and Counsel
    The validity of the issuance of securities registered hereby is passed on for the Company by Jeffrey J. Plumer. Mr. Plumer is General Counsel, of the Company and is compensated by the Company as an employee. Mr. Plumer holds 90,615 shares of Company common stock, 95,863 Company restricted stock units that are payable in an equivalent number of shares of Company common stock, up to 20,520 Company performance restricted stock units that are payable in various numbers of shares of Company common stock depending on achievement of certain



    performance milestones, and Company stock options to acquire up to an additional 379,883 shares of Company common stock. Mr. Plumer is eligible to receive additional stock awards by the Company under the 2017 Plan.
    Item 8.    Exhibits.

    The following exhibits are filed herewith or incorporated by reference as part of this Registration Statement:
    Exhibit No.Description
    4.1
    Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on February 12, 2018).
    4.2
    Certificate of Amendment to Amended and Restated Certificate of Incorporation, dated June 12, 2023 (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed on June 14, 2023)
    4.3
    Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed on February 12, 2018).
    4.4
    Specimen certificate evidencing shares of common stock of the Registrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-222478)).
    5*
    Opinion of Counsel (Legality of Shares)
    23.1*
    Consent of independent registered public accounting firm.
    23.2*
    Consent of Counsel (included as part of Exhibit 5).
    24.1*
    Power of Attorney (included on signature page hereto).
    99.1
    2017 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-222478)).
    99.2
    2023 Inducement Incentive Plan (incorporated by reference to Exhibit 99.3 to the Registrant's Registration Form on Form 8-K (File No. 333-274906)
    99.3*
    First Amendment to the Evolus, Inc. 2023 Inducement Incentive Plan
    107*
    Filing fee table

    *    Filed herewith





    SIGNATURES
        Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Newport Beach, State of California, on March 4, 2025.
    EVOLUS, INC.
    /s/ David Moatazedi
    By:David Moatazedi
    President and Chief Executive Officer
        KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints David Moatazedi and Sandra Beaver and each or either of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement on Form S-8, including any and all post-effective amendments and amendments thereto, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
        Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
    SignatureTitleDate
    /s/ David MoatazediPresident, Chief Executive Officer and
    Member of the Board of Directors
    (Principal Executive Officer)
    March 4, 2025
    David Moatazedi
    /s/ Sandra BeaverChief Financial Officer
    (Principal Financial and Accounting Officer)
    March 4, 2025
    Sandra Beaver
    /s/ Vikram MalikChairman of the Board of DirectorsMarch 4, 2025
    Vikram Malik
    /s/ Simone BlankDirectorMarch 4, 2025
    Simone Blank
    /s/ David GillDirectorMarch 4, 2025
    David Gill
    /s/ Karah ParschauerDirectorMarch 4, 2025
    Karah Parschauer



    /s/ Brady StewartDirectorMarch 4, 2025
    Brady Stewart
    /s/ Albert G. White IIIDirectorMarch 4, 2025
    Albert G. White III


    Get the next $EOLS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EOLS

    DatePrice TargetRatingAnalyst
    8/6/2025Buy → Hold
    Needham
    4/17/2025$21.00Buy
    BTIG Research
    1/29/2024$10.00 → $16.00Equal Weight → Overweight
    Barclays
    6/23/2022$18.00Buy
    Needham
    5/12/2022$8.00 → $10.00Underweight → Equal Weight
    Barclays
    1/20/2022$11.00Hold → Buy
    Truist
    11/3/2021$22.00 → $15.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $EOLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Moatazedi David sold $75,361 worth of shares (10,539 units at $7.15), decreasing direct ownership by 3% to 354,388 units (SEC Form 4)

    4 - Evolus, Inc. (0001570562) (Issuer)

    12/29/25 6:42:08 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Avelar Rui sold $16,168 worth of shares (2,261 units at $7.15), decreasing direct ownership by 0.63% to 356,821 units (SEC Form 4)

    4 - Evolus, Inc. (0001570562) (Issuer)

    12/29/25 6:42:00 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Mitchell Tatjana was granted 104,603 shares (SEC Form 4)

    4 - Evolus, Inc. (0001570562) (Issuer)

    10/9/25 4:57:34 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EOLS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue

    Provides 2026 Net Revenue Guidance and Maintains Projection for Full-Year 2026 Profitability1 Preliminary Unaudited Net Revenue of $88.6 Million to $90.6 Million for the Fourth Quarter 2025, Representing 12% to 15% Growth Over the Prior Year; Company Reaffirms an Important Milestone of Positive Non-GAAP Operating Income of $5 Million to $7 Million for Q4 2025 Preliminary Unaudited Net Revenue of $295.5 Million to $297.5 Million for the Full-Year 2025, Representing 11% to 12% Growth Over the Prior Year 2026 Net Revenue Guidance of $327.0 Million to $337.0 Million, Which Represents 11% to 13% Growth from Preliminary Unaudited 2025 Results; Company Remains on Track to Achieve Sustaina

    1/9/26 8:30:00 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in November of non-qualified stock options to purchase an aggregate of 17,871 shares of Evolus and an aggregate of 45,063 restricted stock units (RSUs) of the company's common stock to 13 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus 2023 Inducement Incentive Plan, with a grant and vesting commencement date of November 7, 2025, as an inducement material to the new employees entering into employment with Evolus in accordance with Na

    11/14/25 4:05:00 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evolus Reports Third Quarter 2025 Financial Results

    Total Net Revenue of $69.0 Million for Q3 2025, Up 13% from Q3 2024; Year-To-Date Growth of 10% Global Jeuveau® Net Revenue of $63.2 Million for Q3 2025, Up from $59.7 Million in Q2 2025, Reflecting Sequential Growth That Outperformed Typical Seasonal Trends Evolysse™ Delivered $5.7 Million in Revenue for Q3 2025 Marking the Strongest Hyaluronic Acid (HA) Filler Debut in Over a Decade Company Now Expects to Achieve Positive Non-GAAP Operating Income of $5 Million to $7 Million in Q4 2025; Remains on Track to Achieve Sustainable Annual Profitability1 Beginning in 2026 Reaffirms 2025 Net Revenue Guidance of $295 Million to $305 Million and Non-GAAP Operating Expenses of $208 Million

    11/5/25 4:05:00 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EOLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evolus downgraded by Needham

    Needham downgraded Evolus from Buy to Hold

    8/6/25 7:20:38 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Evolus with a new price target

    BTIG Research initiated coverage of Evolus with a rating of Buy and set a new price target of $21.00

    4/17/25 8:32:06 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evolus upgraded by Barclays with a new price target

    Barclays upgraded Evolus from Equal Weight to Overweight and set a new price target of $16.00 from $10.00 previously

    1/29/24 7:09:38 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EOLS
    SEC Filings

    View All

    Evolus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Evolus, Inc. (0001570562) (Filer)

    1/9/26 8:34:50 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Evolus Inc.

    SCHEDULE 13G/A - Evolus, Inc. (0001570562) (Subject)

    11/14/25 4:43:42 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Evolus Inc.

    SCHEDULE 13G/A - Evolus, Inc. (0001570562) (Subject)

    11/14/25 1:37:11 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EOLS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stewart Brady bought $204,486 worth of shares (30,000 units at $6.82), increasing direct ownership by 51% to 88,629 units (SEC Form 4)

    4 - Evolus, Inc. (0001570562) (Issuer)

    8/18/25 4:28:22 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director White Albert G Iii bought $189,000 worth of shares (20,000 units at $9.45), increasing direct ownership by 66% to 50,378 units (SEC Form 4)

    4 - Evolus, Inc. (0001570562) (Issuer)

    6/10/25 5:04:47 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EOLS
    Leadership Updates

    Live Leadership Updates

    View All

    Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Tatjana Mitchell as its Chief Financial Officer, effective September 8, 2025. Ms. Mitchell has over 20 years of strategic and operational finance leadership across both public and private companies in retail, consumer, data, and technology-driven businesses. She brings a proven track record of driving revenue growth, scaling organizations, and leading transformation efforts through disciplined financial management and strategic execution. Most recently, Ms. Mitchell served as Senior Vice President of Corporate Finance at Experian

    9/8/25 8:30:00 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evolus Announces Appointment of Albert G. White III to Board of Directors

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes

    7/1/24 8:00:00 AM ET
    $COO
    $EOLS
    Ophthalmic Goods
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Nareg Sagherian has joined the Company as Vice President, Head of Global Investor Relations and Corporate Communications. In this role, Nareg will be responsible for interacting with current and prospective investors and managing a strategic investor relations and corporate communications program. Nareg will report to Sandra Beaver, Chief Financial Officer of Evolus. "I am thrilled to welcome Nareg to our team," said Sandra Beaver, Chief Financial Officer of Evolus. "Nareg's unique experience will enable him to drive a successful investor relati

    1/4/24 4:05:00 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EOLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Evolus Inc.

    SC 13G/A - Evolus, Inc. (0001570562) (Subject)

    11/14/24 4:50:28 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Evolus Inc.

    SC 13G/A - Evolus, Inc. (0001570562) (Subject)

    11/14/24 4:00:06 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Evolus Inc.

    SC 13G/A - Evolus, Inc. (0001570562) (Subject)

    11/13/24 5:38:05 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EOLS
    Financials

    Live finance-specific insights

    View All

    Evolus Reports Third Quarter 2025 Financial Results

    Total Net Revenue of $69.0 Million for Q3 2025, Up 13% from Q3 2024; Year-To-Date Growth of 10% Global Jeuveau® Net Revenue of $63.2 Million for Q3 2025, Up from $59.7 Million in Q2 2025, Reflecting Sequential Growth That Outperformed Typical Seasonal Trends Evolysse™ Delivered $5.7 Million in Revenue for Q3 2025 Marking the Strongest Hyaluronic Acid (HA) Filler Debut in Over a Decade Company Now Expects to Achieve Positive Non-GAAP Operating Income of $5 Million to $7 Million in Q4 2025; Remains on Track to Achieve Sustainable Annual Profitability1 Beginning in 2026 Reaffirms 2025 Net Revenue Guidance of $295 Million to $305 Million and Non-GAAP Operating Expenses of $208 Million

    11/5/25 4:05:00 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evolus to Report Third Quarter Financial Results on November 5, 2025

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2025 financial results on Wednesday, November 5, 2025, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a telephoni

    10/22/25 8:00:00 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates

    Global Net Revenue of $69.4 Million for Q2 2025, Up 4% from Q2 2024 in a Market Where Overall U.S. Aesthetic Procedures Decreased; Growth Driven by the Successful Launch of Evolysse™ and Continued Strength in International Markets Evolysse™ Delivered $9.7 Million in Revenue for Q2 2025, Marking the Strongest Filler Launch Quarter in Over a Decade and Providing a Solid Foundation for Second Half Growth Expects to Achieve Meaningful Profitability1 in Q4 2025 and Annual Profitability1 Beginning in 2026; Strategic Cost Structure Optimization Expected to Yield At Least $25 Million in Non-GAAP Operating Expense Savings for 2025 Resets 2025 Net Revenue Guidance to $295 Million to $305 Mi

    8/5/25 4:05:00 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care